July 23, 2017 1:55 AM ET


Company Overview of Afexa Life Sciences Inc.

Company Overview

Afexa Life Sciences Inc., a health-sciences and technology company, engages in the discovery, development, and commercialization of natural health products for disease prevention and health maintenance in the United States and Canada. The company’s products include COLD-FX, which is designed to prevent and treat colds and flu by strengthening the immune system; CELL-FX, a natural product that helps relieve symptoms of bone and joint pain, and helps in the formation of connective tissue; IMMUNITY-FX, a product that strengthens and supports the immune system; and REMEMBER-FX, a natural health product intended to help restore mental alertness or wakefulness when experiencing fatigue or drowsine...

9604-20th Avenue

Edmonton, AB T6N 1G1


Founded in 1992

126 Employees





Key Executives for Afexa Life Sciences Inc.

Chief Executive Officer, President and Director
Co-Founder and Chief Scientific officer
Chief Marketing Officer and Senior Vice President of Sales
Senior Director of Investor Relations and Corporate Secretary
Chief Legal Officer and Senior Vice President of Corporate Development
Compensation as of Fiscal Year 2017.

Afexa Life Sciences Inc. Key Developments

Judge Tosses Lawsuit over Cold-fX Claims

A judge has tossed out a unique class-action lawsuit that alleged the makers of one of natural-health product misled customers about the remedy's cold-fighting benefits. Justice Janice Dillon of the Supreme Court of British Columbia refused to 'certify' the suit, ruling on November 16, 2016, there was no evidence a group of people had a common grievance against the manufacturer of Cold-fX, as class-action law requires. Cold-fX was developed by Alberta-based Afexa Life Sciences, which was bought by Quebec's Valeant Pharmaceuticals Inc. in 2011. The suit charged that until recent years the firm claimed Cold-fX could bring 'immediate relief' to cold and flu symptoms, despite a lack of evidence. In fact, a company-funded study disclosed as part of the case found that it did no better than a placebo for that purpose. Some scientific evidence suggests that Cold-fX helps slightly reduce the number or severity of viruses in users who take the product daily for two to six months. The B.C. case was unusual among health-product class actions, charging not that the ginseng-based pills caused physical harm, but that their benefits were misrepresented. Dillon did not comment on whether the Cold-fX marketers had misled consumers, but said there was no evidence of a class of people who felt aggrieved - beyond Don Harrison, the 'representative' plaintiff. And it's unclear if even he was swayed by the allegedly misleading promotion.

Similar Private Companies By Industry

Company Name Region
4everPets Ltd. Americas
9037136 Canada Inc. Americas
AAA Heidelberg Inc. Americas
Ab Biotech Inc. Americas
AB Laboratories Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Afexa Life Sciences Inc., please visit www.afexa.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.